2024年6月13日 · CD138 is expressed in most triple negative breast cancers (TNBC). The increased expression of CD138 may contribute to the formation of a tumor supportive microenvironment, promoting the aggressive growth and invasion of cancer cells that are commonly noted in TNBC.

CD138 expression is a hallmark of plasma cells and multiple myeloma cells. However, decreased expression of CD138 is frequently observed in plasma cells of myeloma patients, although the clinical significance of this is unclear.

3 天之前 · CD138-deficient plasma cells show impaired immunoglobulin secretion due to disrupted vesicle docking and fusion. This impairment can lead to intracellular immunoglobulin accumulation, as seen in plasma cell disorders characterized by Russell bodies. CD138 also stabilizes plasma cell survival signals within their microenvironment.

CD138 is a protein found on the surface of certain cells in the body. It plays a role in cell communication and adhesion, which means it helps cells stick together and send signals to each other. This protein is also known as syndecan-1.

Syndecan-1 is a sponge for growth factors and chemokines, [7] with binding largely via heparan sulfate chains. The syndecans mediate cell binding, cell signaling, and cytoskeletal organization and syndecan receptors are required for internalization of the HIV-1 tat protein.

Syndecan-1 (CD138) is a transmembrane proteoglycan known to be expressed in various normal and malignant tissues. It is of interest because of a possible prognostic role of differential expression in tumors and its role as a target for indatuximab, a monoclonal antibody coupled with a cytotoxic agent.

2019年9月12日 · A 69-year-old man with a history of CD138 − plasma cell myeloma (PCM) who received chemotherapy regimens and stem cell transplant presented for bone marrow biopsy, which revealed sheets of atypical plasma cells with abundant amphophilic cytoplasm, occasional binucleation, and distinct perinuclear hof (panels A-B; original magnification ×100 ...